MPM Bioimpact LLC purchased a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 950,000 shares of the company's stock, valued at approximately $11,504,000. Replimune Group accounts for about 1.6% of MPM Bioimpact LLC's holdings, making the stock its 29th largest holding. MPM Bioimpact LLC owned approximately 1.39% of Replimune Group at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of REPL. JPMorgan Chase & Co. raised its holdings in Replimune Group by 3.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock valued at $2,733,000 after buying an additional 8,074 shares during the period. SG Americas Securities LLC increased its stake in Replimune Group by 14.7% in the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after purchasing an additional 3,374 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after purchasing an additional 3,177 shares during the period. Rhumbline Advisers increased its stake in Replimune Group by 8.3% in the fourth quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock worth $1,156,000 after purchasing an additional 7,317 shares during the period. Finally, New York State Common Retirement Fund increased its stake in Replimune Group by 260.8% in the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock worth $523,000 after purchasing an additional 31,231 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $19.43.
Check Out Our Latest Stock Report on REPL
Replimune Group Stock Up 2.4%
Shares of Replimune Group stock traded up $0.19 during trading on Monday, hitting $8.04. 313,449 shares of the stock traded hands, compared to its average volume of 901,925. The firm has a market cap of $619.20 million, a P/E ratio of -2.61 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The stock's fifty day simple moving average is $8.95 and its 200 day simple moving average is $11.32.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, equities analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
